A new congressional report reveals major private student loan companies are aggressively expanding in anticipation of a borrower surge, driven by recent federal lending cuts, raising alarms among Democratic lawmakers about reduced competition and consumer risks.
Ripple has secured a final Electronic Money Institution (EMI) license from Luxembourg's financial watchdog, the CSSF, transitioning from preliminary approval. This key regulatory milestone enables the blockchain payments firm to scale its 'Ripple Payments' service across the European Union's single market.
The medtech giant inaugurates a Centre of Excellence in Swords, aiming to accelerate development of its Atellica diagnostic systems and bolster Ireland's life sciences sector amid strategic corporate shifts.
Revvity (NYSE: RVTY) surged past fourth-quarter expectations and issued an upbeat 2026 outlook, driven by robust demand in its diagnostics division. The medical equipment maker's performance highlights a sector-wide resilience despite ongoing softness in academic research funding.
As Bangladesh heads to the polls on February 12 under an interim government, its geopolitical alignments are shifting. The outcome will test the influence of regional powers India, China, and Pakistan in a nation navigating a post-Hasina political landscape.
A new bilateral trade agreement between the United States and Guatemala aims to eliminate tariffs and streamline preferential treatment for textiles and apparel, a move hailed by U.S. industry leaders as a strategic step to reinforce regional manufacturing networks and counter Asian dominance.
Qatar has tripled its flagship venture capital fund to $3 billion, adding a strategic sweetener: subsidized access to AI computing power. The move aims to position Doha as a competitive hub for tech talent and deep-tech startups in the Gulf region.
Amid a mixed market backdrop, penny stocks are drawing renewed attention for their growth potential. We analyze three standout picks, led by financial services firm Siebert Financial, highlighting their financial health and strategic moves in a volatile landscape.
U.S. stock futures pointed to a lower open Monday as investors braced for a flood of corporate earnings and crucial labor market reports that could sway Federal Reserve policy expectations.
The payments giants Visa and Mastercard reported robust revenue and earnings growth for their latest quarters, though their premium valuations continue to spark investor debate on which offers the superior long-term opportunity.
The global payments giant reported a 15% surge in net revenue and processed a record 69.4 billion transactions in its fiscal first quarter, signaling resilient consumer confidence and a rebound from previous quarters.
Former President Donald Trump has announced Kevin Warsh, a former Federal Reserve governor and economic advisor, as his pick to lead the central bank. The nomination comes as incumbent Chair Jerome Powell faces a federal investigation related to his congressional testimony.
Amgen has transferred full rights for the atopic dermatitis drug rocatinlimab back to Kyowa Kirin, clearing the path for the Japanese firm to pursue US approval by 2026. The move comes despite the drug meeting all trial endpoints, reflecting Amgen's portfolio reprioritization and a tempered market outlook for the OX40 inhibitor class.
Pharmaceutical giant Eli Lilly enters a strategic collaboration potentially worth up to $1.93 billion with biotech firm Repertoire Immune Medicines, aiming to develop precision treatments for autoimmune diseases that move beyond broad immunosuppression.
Insurance brokerage giant Arthur J. Gallagher reported robust fourth-quarter profit growth, driven by resilient demand. However, Truist Securities has lowered its price target on the stock, citing valuation pressures across the property & casualty brokerage sector.
UBS analyst Peter Grom increased his price target for Kimberly-Clark (KMB) to $110, citing steady core performance despite lingering Kenvue-related uncertainties, after the consumer goods giant reported better-than-expected quarterly profit driven by cost discipline and resilient demand.
As the U.S. Treasury prepares its quarterly debt issuance update, bond dealers are on high alert for any shift in strategy aimed at managing soaring yields. While major changes are seen as unlikely, the administration's broader financial interventions have markets questioning the long-held "regular and predictable" borrowing mantra.
A provocative analysis suggests the widespread adoption of GLP-1 drugs like Ozempic and Wegovy could trim airline fuel bills by reducing passenger weight, potentially passing savings to travelers. But industry experts debate whether the math adds up.
Amid a mixed market landscape, corporate insiders are placing significant bets on select small-cap stocks. We analyze three companies where recent insider buying and strategic moves signal potential value, despite broader economic headwinds.
Rising global defense budgets are accelerating the adoption of artificial intelligence in military systems, with companies racing to develop advanced sensing and threat-detection capabilities through strategic partnerships and acquisitions.
